Clinical experience with recombinant molecules for allergy vaccination.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Current Topics in Microbiology and Immunology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/82_2011_129PMID 21562972
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunological mechanisms of allergen‐specific immunotherapy

  2011cited by this paper
• Clinical trials with recombinant allergens--three perspectives: industry.

  2009cited by this paper
• Extensive IgE Cross-Reactivity towards the Pooideae Grasses Substantiated for a Large Number of Grass-Pollen-Sensitized Subjects

  2009cited by this paper
• Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy

  2009influential reference
• Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

  2008cited by this paper
• Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives

  2008cited by this paper
• Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years.

  2008cited by this paper
• Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy

  2007cited by this paper
• Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome.

  2007cited by this paper
• Design, engineering and in vitro evaluation of MHC class‐II targeting allergy vaccines

  2007cited by this paper
• Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis

  2007cited by this paper
• Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.

  2007cited by this paper
• A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi‐sensitivities

  2007cited by this paper
• Modified recombinant allergens for safer immunotherapy.

  2006cited by this paper
• Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.

  2006cited by this paper
• Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.

  2006cited by this paper
• Molecular approaches for new vaccines against allergy

  2006cited by this paper
• Immunological mechanisms of allergen-specific immunotherapy

  2006cited by this paper
• Allergen-specific immunotherapy with recombinant grass pollen allergens.

  2005cited by this paper
• Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1

  2005cited by this paper
• Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity.

  2005cited by this paper
• Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells

  2004cited by this paper
• Vaccination with genetically engineered allergens prevents progression of allergic disease

  2004cited by this paper
• IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

  2003cited by this paper
• Formation of Disulfide Bonds and Homodimers of the Major Cat Allergen Fel d 1 Equivalent to the Natural Allergen by Expression in Escherichia coli*

  2003cited by this paper
• Characteristics and Immunobiology of Grass Pollen Allergens

  2003cited by this paper
• Size exclusion chromatography as a tool for quality control of recombinant allergens and hypoallergenic variants.

  2003cited by this paper
• Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System™

  2002cited by this paper
• Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1

  2001cited by this paper
• Bypassing IgE and targeting T cells for specific immunotherapy of allergy.

  2001cited by this paper
• Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity.

  2000cited by this paper
• The antigen dose determines T helper subset development by regulation of CD40 ligand

  2000cited by this paper
• Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild‐type by skin prick and intradermal testing: results obtained in a French population

  2000cited by this paper
• T Cell Epitope-Containing Hypoallergenic Recombinant Fragments of the Major Birch Pollen Allergen, Bet v 1, Induce Blocking Antibodies1

  2000cited by this paper
• Role of interleukin 10 in specific immunotherapy.

  1998cited by this paper
• Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

  1997cited by this paper
• Genetic detoxification of bacterial toxins: a new approach to vaccine development.

  1995cited by this paper
• Akuttherapie anaphylaktoider Reaktionen: Ergebnisse einer interdisziplinären Consensuskonferenz

  1994cited by this paper
• [Acute therapy of anaphylactoid reactions. Results of an intradisciplinary consensus conference].

  1994cited by this paper
• Serum-IgE-facilitated allergen presentation in atopic disease.

  1993cited by this paper
• Bee venom phospholipase A2‐specific T cell clones from human allergic and non‐allergic individuals: cytokine patterns change in response to the antigen concentration

  1992influential reference
• Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis

  1991influential reference
• The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene.

  1989cited by this paper
• Isolation and characterization of messenger RNA from male inflorescences and pollen of the white birch (Betula verrucosa).

  1988cited by this paper
• Standardized extracts modified allergens-allergoids

  1987cited by this paper

• Genuine and cross-reactive allergenic molecules of birch and hazel

  2021cites this paper
• Potency of T-Cell Epitope-Based Peptide Vaccines in Food Allergy Treatment

  2019cites this paper
• GRAZAX®: a sublingual immunotherapy vaccine for Hay fever treatment: from concept to commercialization

  2019cites this paper
• Bet v 1 and its Homologs: Triggers of Tree-Pollen Allergy and Birch Pollen-Associated Cross-Reactions

  2017cites this paper
• EAACI Molecular Allergology User's Guide

  2016cites this paper
• Immunotherapy (oral and sublingual) for food allergy to fruits.

  2015cites this paper
• Bet v 1 und Homologe: Verursacher der Baumpollenallergie und Birkenpollen-assoziierter Kreuzreaktionen

  2015cites this paper
• [Personalised medicine for the diagnosis and treatment of allergic diseases].

  2013cites this paper
• Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis

  2013cites this paper
• Personalisierte Ansätze zur Diagnostik und Therapie von Allergien

  2013cites this paper
• Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications

  2013cites this paper
• Parthenium dermatitis in India: past, present and future.

  2012cites this paper
• Parthenium dermatitis

  2012cites this paper